JP2016530239A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016530239A5 JP2016530239A5 JP2016525434A JP2016525434A JP2016530239A5 JP 2016530239 A5 JP2016530239 A5 JP 2016530239A5 JP 2016525434 A JP2016525434 A JP 2016525434A JP 2016525434 A JP2016525434 A JP 2016525434A JP 2016530239 A5 JP2016530239 A5 JP 2016530239A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- clostridium cluster
- bacteria
- butyrate
- flagellin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 20
- 241000193403 Clostridium Species 0.000 claims 15
- 241000894006 Bacteria Species 0.000 claims 12
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 claims 5
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims 5
- 108010040721 Flagellin Proteins 0.000 claims 5
- 206010061218 Inflammation Diseases 0.000 claims 5
- 230000002708 enhancing effect Effects 0.000 claims 5
- 230000001939 inductive effect Effects 0.000 claims 5
- 230000004054 inflammatory process Effects 0.000 claims 5
- 210000005027 intestinal barrier Anatomy 0.000 claims 5
- 230000007358 intestinal barrier function Effects 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 3
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims 3
- 239000000427 antigen Substances 0.000 claims 3
- 102000036639 antigens Human genes 0.000 claims 3
- 108091007433 antigens Proteins 0.000 claims 3
- 230000000694 effects Effects 0.000 claims 3
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 claims 3
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 208000035473 Communicable disease Diseases 0.000 claims 2
- 102000003964 Histone deacetylase Human genes 0.000 claims 2
- 108090000353 Histone deacetylase Proteins 0.000 claims 2
- 102000043131 MHC class II family Human genes 0.000 claims 2
- 108091054438 MHC class II family Proteins 0.000 claims 2
- UYXTWWCETRIEDR-UHFFFAOYSA-N Tributyrin Chemical compound CCCC(=O)OCC(OC(=O)CCC)COC(=O)CCC UYXTWWCETRIEDR-UHFFFAOYSA-N 0.000 claims 2
- 208000026935 allergic disease Diseases 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 150000004666 short chain fatty acids Chemical class 0.000 claims 2
- 101710151190 Flagellin A Chemical class 0.000 claims 1
- 102100040133 Free fatty acid receptor 2 Human genes 0.000 claims 1
- 101150103290 Hcar2 gene Proteins 0.000 claims 1
- 101000890668 Homo sapiens Free fatty acid receptor 2 Proteins 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- WFVFQUPBGWFLMB-DVYMNCLGSA-N [(3ar,5r,6s,6ar)-5-[(1r)-1,2-dihydroxyethyl]-2,2-dimethyl-3a,5,6,6a-tetrahydrofuro[2,3-d][1,3]dioxol-6-yl] butanoate Chemical compound O1C(C)(C)O[C@@H]2[C@@H](OC(=O)CCC)[C@@H]([C@H](O)CO)O[C@@H]21 WFVFQUPBGWFLMB-DVYMNCLGSA-N 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 229940053200 antiepileptics fatty acid derivative Drugs 0.000 claims 1
- GYKLFBYWXZYSOW-UHFFFAOYSA-N butanoyloxymethyl 2,2-dimethylpropanoate Chemical compound CCCC(=O)OCOC(=O)C(C)(C)C GYKLFBYWXZYSOW-UHFFFAOYSA-N 0.000 claims 1
- 230000000112 colonic effect Effects 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 210000004877 mucosa Anatomy 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 235000021391 short chain fatty acids Nutrition 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361844204P | 2013-07-09 | 2013-07-09 | |
| US61/844,204 | 2013-07-09 | ||
| PCT/US2014/045801 WO2015006355A2 (en) | 2013-07-09 | 2014-07-08 | Compositions containing combinations of bioactive molecules derived from microbiota for treatment of disease |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019092447A Division JP2019189609A (ja) | 2013-07-09 | 2019-05-15 | 微生物叢由来生物活性分子の組み合わせを含む疾患治療用組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016530239A JP2016530239A (ja) | 2016-09-29 |
| JP2016530239A5 true JP2016530239A5 (OSRAM) | 2017-08-17 |
Family
ID=52280706
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016525434A Pending JP2016530239A (ja) | 2013-07-09 | 2014-07-08 | 微生物叢由来生物活性分子の組み合わせを含む疾患治療用組成物 |
| JP2019092447A Pending JP2019189609A (ja) | 2013-07-09 | 2019-05-15 | 微生物叢由来生物活性分子の組み合わせを含む疾患治療用組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019092447A Pending JP2019189609A (ja) | 2013-07-09 | 2019-05-15 | 微生物叢由来生物活性分子の組み合わせを含む疾患治療用組成物 |
Country Status (4)
| Country | Link |
|---|---|
| US (3) | US9764019B2 (OSRAM) |
| EP (1) | EP3019181A4 (OSRAM) |
| JP (2) | JP2016530239A (OSRAM) |
| WO (1) | WO2015006355A2 (OSRAM) |
Families Citing this family (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPQ899700A0 (en) | 2000-07-25 | 2000-08-17 | Borody, Thomas Julius | Probiotic recolonisation therapy |
| WO2011151941A1 (ja) | 2010-06-04 | 2011-12-08 | 国立大学法人東京大学 | 制御性ｔ細胞の増殖または集積を誘導する作用を有する組成物 |
| CA2807242C (en) | 2010-08-04 | 2017-05-02 | Thomas Julius Borody | Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them |
| AU2012225305B2 (en) | 2011-03-09 | 2017-06-08 | Regents Of The University Of Minnesota | Compositions and methods for transplantation of colon microbiota |
| GB201112091D0 (en) | 2011-07-14 | 2011-08-31 | Gt Biolog Ltd | Bacterial strains isolated from pigs |
| GB201117313D0 (en) | 2011-10-07 | 2011-11-16 | Gt Biolog Ltd | Bacterium for use in medicine |
| JP6306507B2 (ja) | 2011-12-01 | 2018-04-18 | 国立大学法人 東京大学 | 制御性ｔ細胞の増殖または集積を誘導するヒト由来細菌 |
| US9719144B2 (en) | 2012-05-25 | 2017-08-01 | Arizona Board Of Regents | Microbiome markers and therapies for autism spectrum disorders |
| GB201306536D0 (en) | 2013-04-10 | 2013-05-22 | Gt Biolog Ltd | Polypeptide and immune modulation |
| EP3019181A4 (en) * | 2013-07-09 | 2016-09-21 | Puretech Ventures Llc | COMPOSITIONS WITH COMBINATIONS OF BIOACTIVE MOLECULARS DERIVED FROM MICROBOTS FOR TREATING DISEASES |
| KR102259934B1 (ko) | 2013-11-27 | 2021-06-03 | 에픽스 테라퓨틱스 | 염증 질환의 치료에 사용되기 위한 화합물, 의약 조성물 및 방법 |
| MA41020A (fr) | 2014-11-25 | 2017-10-03 | Evelo Biosciences Inc | Compositions probiotiques et prébiotiques, et leurs procédés d'utilisation pour la modulation du microbiome |
| CA2970234A1 (en) | 2014-12-23 | 2016-06-30 | 4D Pharma Research Limited | Pirin polypeptide and immune modulation |
| EA202090948A1 (ru) | 2014-12-23 | 2020-11-30 | 4Д Фарма Рисерч Лимитед | Иммуномодуляция |
| MX387817B (es) | 2015-01-23 | 2025-03-11 | Univ Temple | Uso de acidos grasos de cadena corta en prevencion de cancer. |
| CN114159476A (zh) | 2015-05-14 | 2022-03-11 | 克雷斯顿沃控股公司 | 用于粪便菌群移植的组合物以及用于制备和使用它们的方法和用于递送它们的装置 |
| US20160339065A1 (en) | 2015-05-22 | 2016-11-24 | Arizona Board Of Regents On Behalf Of Arizona State University | Methods for Treating Autism Spectrum Disorder and Associated Symptoms |
| PT3240554T (pt) | 2015-06-15 | 2019-11-04 | 4D Pharma Res Ltd | Blautia stercosis e wexlerae para uso no tratamento de doenças inflamatórias e autoimunes |
| PT3307288T (pt) | 2015-06-15 | 2019-10-17 | 4D Pharma Res Ltd | Composições compreendendo estirpes bacterianas |
| MA41010B1 (fr) | 2015-06-15 | 2020-01-31 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
| MA41060B1 (fr) | 2015-06-15 | 2019-11-29 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
| MA55434B1 (fr) | 2015-06-15 | 2022-02-28 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
| GB201520497D0 (en) | 2015-11-20 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| BR112018010089A2 (pt) | 2015-11-20 | 2018-11-13 | 4D Pharma Res Ltd | composições compreendendo cepas bacterianas |
| GB201520638D0 (en) | 2015-11-23 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| GB201520631D0 (en) | 2015-11-23 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| AU2017226831B2 (en) | 2016-03-04 | 2018-10-04 | 4D Pharma Plc | Compositions comprising bacterial Blautia strains for treating visceral hypersensitivity |
| GB201612191D0 (en) | 2016-07-13 | 2016-08-24 | 4D Pharma Plc | Compositions comprising bacterial strains |
| CA3226196A1 (en) | 2016-06-14 | 2017-12-21 | Vedanta Biosciences, Inc. | Treatment of clostridium difficile infection |
| US9999641B2 (en) | 2016-06-14 | 2018-06-19 | Vedanta Biosciences, Inc. | Treatment of clostridium difficile infection |
| US20170360848A1 (en) | 2016-06-15 | 2017-12-21 | Arizona Board Of Regents On Behalf Of Arizona State University | Methods for treating autism spectrum disorder and associated symptoms |
| US10849936B2 (en) | 2016-07-01 | 2020-12-01 | Regents Of The University Of Minnesota | Compositions and methods for C. difficile treatment |
| TW201821093A (zh) | 2016-07-13 | 2018-06-16 | 英商４Ｄ製藥有限公司 | 包含細菌菌株之組合物 |
| US20180036352A1 (en) | 2016-08-03 | 2018-02-08 | Crestovo Holdings Llc | Methods for treating ulcerative colitis |
| US10092601B2 (en) | 2016-10-11 | 2018-10-09 | Crestovo Holdings Llc | Compositions and methods for treating multiple sclerosis and related disorders |
| US11026978B2 (en) | 2016-10-11 | 2021-06-08 | Finch Therapeutics Holdings Llc | Compositions and methods for treating multiple sclerosis and related disorders |
| WO2018071536A1 (en) | 2016-10-11 | 2018-04-19 | Crestovo Holdings Llc | Compositions and methods for treating primary sclerosing cholangitis and related disorders |
| GB201621123D0 (en) | 2016-12-12 | 2017-01-25 | 4D Pharma Plc | Compositions comprising bacterial strains |
| US11065217B2 (en) | 2017-01-27 | 2021-07-20 | Temple University—Of the Commonwealth System of Higher Education | Use of short chain fatty acids for the treatment and prevention of diseases and disorders |
| KR102646764B1 (ko) * | 2017-01-27 | 2024-03-13 | 템플 유니버시티-오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 | 질환 및 장애의 치료 및 방지를 위한 단쇄 지방산의 용도 |
| CA3058943C (en) | 2017-04-03 | 2023-10-17 | Gusto Global, Llc | Rational design of microbial-based biotherapeutics |
| AU2018250206A1 (en) | 2017-04-05 | 2019-10-31 | Crestovo Holdings Llc | Compositions and methods for treating parkinson's disease (PD) and related disorders |
| WO2018187464A1 (en) | 2017-04-05 | 2018-10-11 | Crestovo Holdings Llc | Compositions and methods for treating diverticulitis and related disorders |
| KR102665545B1 (ko) | 2017-04-17 | 2024-05-13 | 더 유니버서티 오브 시카고 | 인간 건강에의 적용 및 질환의 치료를 위한 장으로의 단쇄 지방산의 전달을 위한 중합체 재료 |
| HUE054164T2 (hu) | 2017-05-22 | 2021-08-30 | 4D Pharma Res Ltd | Baktériumtörzseket tartalmazó készítmények |
| WO2018215782A1 (en) | 2017-05-24 | 2018-11-29 | 4D Pharma Research Limited | Compositions comprising bacterial strain |
| EP3630190B1 (en) | 2017-05-26 | 2024-02-21 | Finch Therapeutics Holdings LLC | Lyophilized compositions comprising fecal microbe-based therapeutic agents and methods for making and using same |
| JP6884889B2 (ja) | 2017-06-14 | 2021-06-09 | フォーディー ファーマ リサーチ リミテッド４Ｄ Ｐｈａｒｍａ Ｒｅｓｅａｒｃｈ Ｌｉｍｉｔｅｄ | 細菌株を含む組成物 |
| PL3600363T3 (pl) | 2017-06-14 | 2021-06-14 | 4D Pharma Research Limited | Kompozycje zawierające szczepy bakteryjne |
| SMT202000555T1 (it) | 2017-06-14 | 2020-11-10 | 4D Pharma Res Limited | Composizioni comprendenti un ceppo batterico del genere megaspaera e loro usi |
| DE102017115819A1 (de) * | 2017-07-13 | 2019-01-17 | Aiden Haghikia | Mittel zur prophylaktischen und/oder unterstützenden therapeutischen Behandlung von Morbus Parkinson |
| WO2019032573A1 (en) | 2017-08-07 | 2019-02-14 | Finch Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR MAINTAINING AND RESTORING A HEALTHY INTESTINAL BARRIER |
| WO2019152344A1 (en) * | 2018-01-30 | 2019-08-08 | University Of Louisville Research Foundation, Inc. | Compositions and methods for treating inflammation and cancer |
| KR20210016407A (ko) | 2018-06-05 | 2021-02-15 | 플래그쉽 파이어니어링 이노베이션스 브이, 인크. | 대사 장애 및 비알코올성 지방 간 질환의 치료를 위한 활성제 및 그 사용 방법 |
| US11166990B2 (en) | 2018-07-13 | 2021-11-09 | Finch Therapeutics Holdings Llc | Methods and compositions for treating ulcerative colitis |
| EP3836946A4 (en) | 2018-08-17 | 2022-05-04 | Vedanta Biosciences, Inc. | METHOD OF REDUCING DYSBIosis AND RECOVERING A MICROBIOME |
| JP2022514145A (ja) | 2018-09-27 | 2022-02-10 | フィンチ セラピューティクス ホールディングス エルエルシー | てんかんおよび関連する障害を治療するための組成物および方法 |
| JP7444459B2 (ja) * | 2018-10-04 | 2024-03-06 | 国立研究開発法人理化学研究所 | ＩＬＣ２を標的としたＩｇＡ産生誘導方法 |
| EP3999029A4 (en) * | 2019-07-17 | 2023-07-26 | University of Utah Research Foundation | CLOSTRIDIA CONSORTIA COMPOSITIONS AND METHODS OF TREATMENT OF OBESITY, METABOLIC SYNDROME AND IRRITABLE BOWEL |
| BR112022000875A2 (pt) | 2019-07-19 | 2022-03-29 | Finch Therapeutics Holdings Llc | Métodos e produtos para tratamento de distúrbios gastrointestinais |
| WO2021058811A1 (en) * | 2019-09-25 | 2021-04-01 | Philipps-Universität Marburg | Short-chain fatty acid pentanoate as enhancer for cellular therapy and anti-tumor therapy |
| US12397563B2 (en) | 2023-08-24 | 2025-08-26 | Stolle Machinery Company, Llc | Automatic label creator and method for can decorating |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2383662A1 (fr) * | 1977-03-15 | 1978-10-13 | Cassenne Lab Sa | Nouvelles compositions a usage cosmetique |
| DE3069074D1 (en) | 1979-11-16 | 1984-10-04 | Sterosynt Ltd | 6-alpha-9-alpha-difluoro-16-beta-methyl-prednisolone-17,21 diesters and pharmaceutical compositions containing them |
| US5569680A (en) * | 1995-02-13 | 1996-10-29 | Trustees Of The Univ. Of Penna | Method of treating inflammatory bowel disease with tributyrin |
| US6368586B1 (en) | 1996-01-26 | 2002-04-09 | Brown University Research Foundation | Methods and compositions for enhancing the bioadhesive properties of polymers |
| CA2440474A1 (en) | 2001-04-05 | 2002-10-17 | Virginia Mason Research Center | Methods of mhc class ii epitope mapping, detection of autoimmune t cells and antigens, and autoimmune treatment |
| EP1743654A1 (en) | 2005-07-15 | 2007-01-17 | TopoTarget Germany AG | Use of inhibitors of histone deacetylases in combination with NSAID for the therapy of cancer and/or inflammatory diseases |
| GB0903016D0 (en) | 2009-02-23 | 2009-04-08 | Univ Gent | Method for alleviating intestinal problems and novel bacterial strains therefor |
| GB201117313D0 (en) | 2011-10-07 | 2011-11-16 | Gt Biolog Ltd | Bacterium for use in medicine |
| EP3019181A4 (en) | 2013-07-09 | 2016-09-21 | Puretech Ventures Llc | COMPOSITIONS WITH COMBINATIONS OF BIOACTIVE MOLECULARS DERIVED FROM MICROBOTS FOR TREATING DISEASES |
-
2014
- 2014-07-08 EP EP14822228.4A patent/EP3019181A4/en not_active Ceased
- 2014-07-08 WO PCT/US2014/045801 patent/WO2015006355A2/en not_active Ceased
- 2014-07-08 US US14/903,377 patent/US9764019B2/en active Active
- 2014-07-08 JP JP2016525434A patent/JP2016530239A/ja active Pending
-
2017
- 2017-08-18 US US15/680,629 patent/US10130695B2/en not_active Expired - Fee Related
-
2018
- 2018-10-15 US US16/160,869 patent/US20190134179A1/en not_active Abandoned
-
2019
- 2019-05-15 JP JP2019092447A patent/JP2019189609A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016530239A5 (OSRAM) | ||
| Peloquin et al. | Mechanisms of pediatric inflammatory bowel disease | |
| Fleischmann et al. | Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial | |
| Chervy et al. | Adherent-Invasive E. coli: Update on the Lifestyle of a Troublemaker in Crohn’s Disease | |
| Huang et al. | Skin manifestations of inflammatory bowel disease | |
| Miehlke et al. | Budesonide is more effective than mesalamine or placebo in short-term treatment of collagenous colitis | |
| Hansen et al. | Therapeutic manipulation of the microbiome in IBD: current results and future approaches | |
| Burke et al. | Modifiable environmental factors in inflammatory bowel disease | |
| Bamias et al. | New insights into the dichotomous role of innate cytokines in gut homeostasis and inflammation | |
| JP2012126736A5 (OSRAM) | ||
| Hauso et al. | 5-Aminosalicylic acid, a specific drug for ulcerative colitis | |
| JP2019189609A (ja) | 微生物叢由来生物活性分子の組み合わせを含む疾患治療用組成物 | |
| Regna et al. | Class I and II histone deacetylase inhibition by ITF2357 reduces SLE pathogenesis in vivo | |
| JP2018039833A5 (OSRAM) | ||
| JP2015517489A5 (OSRAM) | ||
| JP2012515213A5 (OSRAM) | ||
| Steinert et al. | Gastro-intestinal tract: The leading role of mucosal immunity | |
| Opoku et al. | Intestinal microbiome–rheumatoid arthritis crosstalk: The therapeutic role of probiotics | |
| JP2017533220A5 (OSRAM) | ||
| Salvadori et al. | Microbiota, renal disease and renal transplantation | |
| JP2016512247A5 (OSRAM) | ||
| Zheng et al. | Treatment of pediatric refractory Crohn’s disease with thalidomide | |
| JP2017519763A5 (OSRAM) | ||
| Bu et al. | Gut microbiota and intestinal immunity interaction in ulcerative colitis and its application in treatment | |
| Azzman | Crohn’s disease: Potential drugs for modulation of autophagy |